Ahmadmehrabi Shadi, Tang W H Wilson
aCleveland Clinic Lerner College of Medicine at Case Western Reserve UniversitybHeart and Vascular InstitutecCenter for Clinical Genomics, Cleveland Clinic, Cleveland, Ohio, USA.
Curr Opin Cardiol. 2017 Nov;32(6):761-766. doi: 10.1097/HCO.0000000000000445.
In recent years, an interest in intestinal microbiota-host interactions has increased due to many findings about the impact of gut bacteria on human health and disease. Dysbiosis, a change in the composition of the gut microbiota, has been associated with much pathology, including cardiovascular diseases (CVD). This article will review normal functions of the gut microbiome, its link to CVD, and potential therapeutic interventions.
The recently discovered contribution of gut microbiota-derived molecules in the development of heart disease and its risk factors has significantly increased attention towards the connection between our gut and heart. The gut microbiome is virtually an endocrine organ, arguably the largest, capable of contributing to and reacting to circulating signaling molecules within the host. Gut microbiota-host interactions occur through many pathways, including trimethylamine-N-oxide and short-chain fatty acids. These molecules and others have been linked to much pathology including chronic kidney disease, atherosclerosis, and hypertension.
Although our understanding of gut microbiota-host interactions has increased recently; many questions remain about the mechanistic links between the gut microbiome and CVD. With further research, we may one day be able to add gut microbiota profiles as an assessable risk factor for CVD and target therapies towards the gut microbiota.
近年来,由于关于肠道细菌对人类健康和疾病影响的诸多发现,人们对肠道微生物群与宿主相互作用的兴趣有所增加。肠道微生物群组成的改变即生态失调,与包括心血管疾病(CVD)在内的多种病理状况相关。本文将综述肠道微生物组的正常功能、其与心血管疾病的联系以及潜在的治疗干预措施。
最近发现肠道微生物群衍生分子在心脏病及其危险因素的发展中所起的作用,显著增加了人们对肠道与心脏之间联系的关注。肠道微生物组实际上是一个内分泌器官,可以说是最大的内分泌器官,能够对宿主内循环的信号分子产生影响并做出反应。肠道微生物群与宿主的相互作用通过多种途径发生,包括氧化三甲胺和短链脂肪酸。这些分子以及其他分子与包括慢性肾病、动脉粥样硬化和高血压在内的多种病理状况有关。
尽管我们最近对肠道微生物群与宿主相互作用的理解有所增加,但关于肠道微生物组与心血管疾病之间的机制联系仍有许多问题。随着进一步的研究,也许有一天我们能够将肠道微生物群谱作为心血管疾病的一个可评估危险因素,并针对肠道微生物群进行靶向治疗。